Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.60 |
| ▸ | KDR | P35968 | 12/20 | 0.58 |
| ▸ | LCK | P06239 | 11/20 | 0.58 |
| ▸ | FYN | P06241 | 11/20 | 0.58 |
| ▸ | YES1 | P07947 | 11/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830656 | 1.00 | SRC (0.60) | SRCKDRLCKFYNYES1 | |
| SCHEMBL6696751 | 0.87 | SRC (0.59) | SRCKDRLCKFYNYES1 | |
| SCHEMBL6704004 | 0.85 | SRC (0.72) | SRCKDRLCKFYNYES1 | |
| SCHEMBL5830905 | 0.82 | SRC (0.71) | SRCKDRLCKFYNYES1 | |
| SCHEMBL5830903 | 0.82 | SRC (0.71) | SRCKDRLCKFYNYES1 | |
| SCHEMBL5830698 | 0.81 | SRC (0.57) | SRCKDRLCKFYNYES1 | |
| SCHEMBL5830702 | 0.81 | SRC (0.57) | SRCKDRLCKFYNYES1 | |
| SCHEMBL140057 | 0.79 | PDGFRB (0.65) | SRCKDRLCKFYNYES1 | |
| SCHEMBL154916 | 0.79 | PDGFRB (0.65) | SRCKDRLCKFYNYES1 | |
| SCHEMBL6701507 | 0.79 | SRC (0.72) | SRCKDRLCKFYNYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010048273-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-7053086-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-05-20 | — | — | US | disclosed |
| US-6635640-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | SRC 4767/4885KDR 4431/4885LCK 4772/4885 |
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | SRC 458/4885KDR 1114/4885LCK 405/4885 |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | SRC 458/4885KDR 1114/4885LCK 405/4885 |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | SRC 4733/4885KDR 4776/4885LCK 4614/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | SRC 3663/4885KDR 4866/4885LCK 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.